Diabetes is a worldwide pandemic calling for innovation in therapeutic prevention and cure. Mounting evidence attribute the involvement of multiple immune dysfunctions in both type 1 diabetes (T1D, caused by autoimmunity) and type 2 diabetes (T2D, caused by insulin resistance).

"Stem Cell Educator therapy" is the innovative technology developed by Dr. Yong Zhao that uses stem cells drawn from adult human blood to targets autoimmune diseases. Currently, Tianhe is focusing on the application of Stem Cell Educator therapy in diabetes. Our clinical data provide powerful evidence that Stem Cell Educator therapy can balance the immune system and lead to the regeneration of islet beta cells and improve metabolic control in long-standing diabetic subjects. This groundbreaking technology is taking steps towards the ultimate cure of diabetes and revolutionizing the treatment of other autoimmune-related diseases.

Tianhe Stem Cell Biotechnologies Inc. has licensed a series of patented technologies from the isolation of human cord blood-derived multipotent stem cells (CB-SCs) to clinical applications. It has a major division in China, Jinan Tianhe Stem Cell Biotechnology Co., Ltd., located in Jinan High-tech Bioindustry Park District.


 

January 25, 2014 - Tianhe’s international patent on human cord blood stem cells has been granted by European Patent Office. This patent will cover the countries in European Union. 

January 18, 2014 - Stem Cell Educator therapy becomes one of the top 3 technologies to practically cure type 1 diabetes among over 300 current clinical trials in the world. Read more on Juvenile Diabetes Cure Alliance website: Exhibit 10 inState of the Cure 2013.

November 23, 2013 - To advance Stem Cell Educator therapy and find a cure for type 1 diabetes, a new clinical trial was initiated in children with type 1 diabetes, in collaboration with Dr.Zhiguang Zhou at the Second Xiangya Hospital of Central South University (Changsha, China) as well as the apheresis team from Terumo BCT (Denver, USA).

More...